Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cancer drug developer Antisoma, The Institute of Cancer Research and Cancer Research Technology have announced a collaboration and licensing agreement under which Antisoma has acquired rights to develop and commercialize novel anticancer compounds called protein phosphatase magnesium-dependent 1 d inhibitors.
Subscribe to our email newsletter
Work carried out at the Breakthrough Breast Cancer Research Centre and at the Cancer Research UK Centre for Cancer Therapeutics, both of which are at The Institute of Cancer Research (The Institute), showed that these compounds inhibit protein phosphatase magnesium-dependent 1 d (PPM1D) and selectively kill cells that over-express this phosphatase.
Antisoma plans to continue the preclinical development of PPM1D inhibitors from The Institute’s pipeline.
Antisoma and The Institute have also formed a collaboration to explore further the potential of PPM1D-based approaches to cancer treatment. This work will continue to take place at the Breakthrough Breast Cancer Research Centre and the Cancer Research UK Centre for Cancer Therapeutics.
Antisoma will make an immediate upfront payment and fund certain research at The Institute. Further payments will be made on achievement of development and regulatory milestones, and royalties will be paid on any sales of compounds resulting from the collaboration.
Glyn Edwards, Antisoma’s CEO, said: “The Institute’s PPM1D inhibitors are another promising addition to our preclinical portfolio. They fit with our strategy of acquiring a diverse range of novel preclinical compounds with potential to add value to our clinical pipeline in the future.”